PacBio and Verily Health Announce Multi-Year Strategic Collaboration to Scale Long-Read Genomics for Biomedical AI
Key Highlights
- ➤PacBio (PACB) and Verily Health announce a multi-year strategic collaboration.
- ➤Collaboration links PacBio HiFi sequencing with Verily Pre’s governed data and AI platform.
- ➤Verily Pre Workbench will aggregate, analyze, and curate AI-ready HiFi genomic datasets.
- ➤Verily Workbench serves more than 20,000 researchers and has supported more than 700 publications.
- ➤Companies plan to scale long-read programs across biopharma, clinical institutions, and population genomics.
Expert Statements
Stephen Gillett, Chairman and CEO of Verily Health
“This collaboration reflects a shared focus on making high-quality genomic data more accessible and useful across research and development, while creating a foundation for continued innovation in health.”
Stephen Gillett, Chairman and CEO of Verily Health
“Working with PacBio, we hope to deliver a meaningful impact to researchers and innovators working to find new answers for neurology, oncology, rare disease, and other areas of critical unmet need.”
Mark Van Oene, President and CEO of PacBio
“PacBio HiFi sequencing offers our customers the most complete and highest quality data available, which is ideal for training AI models where the input determines the success of the output”
Mark Van Oene, President and CEO of PacBio
“Through this collaboration with Verily Health, we are building a path to turn richer biological data into AI-ready data at scale to ultimately help researchers get more from both their sequencing and their models.”
MENLO PARK, Calif. and DALLAS, Oct. 19, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, and Verily Health Inc., a healthcare data intelligence company, announced today a multi-year strategic collaboration to integrate PacBio HiFi sequencing with Verily Health’s governed data and AI platform. The collaboration will link PacBio sequencing workflows to Verily Pre, combining long-read genomic data with real-world clinical data at population scale. The resulting AI-ready clinico-genomic datasets will support biomedical discovery efforts and AI model training and deployment.
The collaboration addresses a growing bottleneck in biomedical AI: increasingly powerful models require biological data with greater depth, context and scale. Long-read sequencing can reveal complex genetic variants, structural changes, methylation information, and full-length RNA transcripts that are difficult to capture with short-read approaches, offering richer insights into disease biology. Yet, processing these large, complex datasets and integrating them with clinical data for model training remains fragmented, unscalable and largely bespoke. PacBio and Verily Health intend to connect those steps, making rich genomic data more accessible and usable to power the next generation of biomedical AI applications. Verily Pre already supports population-scale biomedical research, while Workbench serves more than 20,000 researchers and has supported more than 700 publications. And because PacBio HiFi whole-genome sequencing workflows already run end-to-end within the Verily Pre environment, it provides an existing and robust technical foundation for the multi-year collaboration.
Get started
Create a free account to read the full story.